Abstract. The present study aimed to investigate changes in cellular immune function and regulatory T cells (Tregs) in patients with hepatocellular carcinoma (HCC) prior to and following transcatheter arterial chemoembolization (TACE) and their clinical significance. The proportion of CD4 + and CD8 + T cells and Tregs in the peripheral blood between healthy volunteers and patients with HCC were detected by flow cytometry prior to (1 day) and one month following TACE.
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-associated mortality worldwide. Since China has a high incidence of hepatitis virus infection, the morbidity of HCC is significantly higher than the world average. Each year China has ~110,000 cases of mortality due to HCC (1) (2) (3) . Numerous factors contribute to the occurrence and development of HCC, among which tumor immune tolerance, is of vital importance. Regulatory T cells (Tregs) are the dominant cells inducing tumor immune tolerance and thus have a significant role in the development of HCC (4) (5) (6) . HCC, with a high degree of malignancy, is often in an advanced stage when it is initially diagnosed. The majority of patients have no opportunity for the tumor to be resected, and therefore, transcatheter arterial chemoembolization (TACE) is the preferred method of treatment (7) . Although this method has been widely used in clinical treatment, whether it effects the expression of Tregs in patients with HCC remains to be elucidated. The present study investigated, from the perspective of tumor immunity, the impact of TACE on Tregs and the cellular immune function of patients with HCC prior to and following TACE. were also used in the present study.
Materials and methods

Patient characteristics.
TACE. A total of 3 ml venous blood was obtained from patients with HCC and healthy individuals with an EDTA-K2 anticoagulants mining vessel (BD Bioscience) 1 day prior to TACE and 1 month following TACE. For TACE, the Seldinger technique was used percutaneously via the right femoral artery for superselective catheter insertion into the right or left hepatic artery, which was determined by the location of the tumor (9) . Subsequently, injection of lipiodol (Di Xin Chemical Co., Ltd., Wuhan, China) and chemotherapeutic drug suspension was administered through the transcatheter, which included lipiodol epirubicin (3-12 ml; Di Xin Chemical Co., Ltd.), epirubicin 30-50 mg and 5-FU (Yezhou Sheng Technology Co., Ltd., Shanghai, China; 1.0 g). The dose of lipiodol and the chemotherapeutic drug were determined according to the size of the tumor and liver function condition. If the tumor diameter was >5 cm the lipiodol dose was 12 ml and the epirubicin dose was 40 mg. If the tumor diameter was <5 cm the lipiodol dose was 6 ml and the epirubicin dose was 40 mg. Gelatin sponge particles were used to embolize the hepatic artery to reduce the rate of blood flow.
Flow cytometry. The-cell surface expression levels of CD4, CD8 and CD25 were evaluated using flow cytometry, followed by incubation with FITC-conjugated anti-CD4 antibody, PE-conjugated anti-CD25 antibody and PE-CY5-conjugated anti-CD8 antibody at room temperature. FITC-conjugated mouse IgG, PE-conjugated mouse IgG or PE-CY5-conjugated mouse IgG (Becton Dickinson) were respectively incubated with the cells as a control. After 10 min, red cells were removed using lysis buffer, and were washed once with PBS. The cells were resuspended in 0.5 ml PBS. Analysis was performed on the results obtained from at least 10,000 cells, which were acquired on a FACSCalibur (BD Bioscience). An ELISA assay was used to determine the content of interleukin (IL)-35 in the peripheral blood, according to the manufacturer's instructions.
Statistical analysis. The data are expressed as the mean ± standard deviation and analyzed using the SPSS 16.0 software package (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. Change of AFP in the peripheral blood of patients with HCC prior to and following TACE. Among the 43 patients diagnosed with HCC who were followed-up during the entire investigation, 32 patients (76.2% of total) were positive for AFP (AFP >20 ng/l). Following TACE (1 month), the quantity of AFP was decreased to 827±981 ng/l, which was markedly lower than prior to TACE (1,647±1,649 ng/l; P<0.05). These results indicated that TACE is effective for the treatment of patients with HCC. 
Results
Alteration of T cell subsets in the peripheral
Correlation of index.
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CT images of patients with HCC prior to and following TACE. The CT images of patients with HCC following TACE (1 month) were assessed and they displayed clear Lipiodol deposition in the tumor region (Fig. 7) If the ratio is significantly lower, the host immune function is weakened and this weakened antitumor effect is conducive to tumorigenesis and development (11) . Several previous studies have substantiated that the immune function of patients with cancer are suppressed, which is predominantly displayed as the decrease of CD4 + , ratio of CD4 + /CD8 + and natural killer (NK) cells; however, the changes in CD8 + occur at different degrees. The present study demonstrated that the proportion of CD4 + cells and the ratio of CD4 + /CD8 + was markedly decreased, while the proportion of CD8 + was significantly increased in the PBMCs of the patients with HCC. These results suggested that the cellular immune function of the patients with HCC was weakened or inhibited.
It is important to understand how the quality and magnitude of the adaptive immune response to nonself-antigens is controlled, so as to avoid damage to the host. Tregs have an indispensable role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host (12). Tregs, as major subsets of the T lymphocyte lineage in the healthy adult, is not only associated with tumor development, but is also important for the treatment and prognosis of the tumor (13) . Immunological self tolerance is maintained, at least in part, by Treg cells, which actively and dominantly control potentially hazardous self-reactive T cells in the periphery (14) . Since the majority of tumor antigens are self-antigens, the host usually maintains immunological unresponsiveness to the early primary tumor. There is a certain association between the formation of this tumor immune tolerance and Tregs. Once Tregs are activated they can suppress CD4 + and CD8 + T cells in a non-antigen-specific manner, thereby inhibiting these effector lymphocyte antitumor responses. Previous studies have demonstrated that the proportion of Tregs in the peripheral blood of patients with cancer is higher compared with that in healthy individuals. Tregs can inhibit the proliferation, differentiation and function of B cells, T helper cells and cytotoxic T cells by the secretion of inhibitory cytokines, including IL-4, IL-10 and transforming growth factor (TGF)-β, and can subsequently directly suppress the proliferation and activity of CD4 + and CD8 + T lymphocytes, NK cells and other immune cells, which performs an immunosuppressive effect, leading to tumor immune tolerance (15) (16) (17) . Other previous studies revealed that the quantity of Treg cells is increased in the peripheral blood and tumor tissue of patients with HCC (18, 19 (15, 24, 25) . Tregs and HCC reinforce each other to create a vicious cycle. If the tumor could be destroyed or excised, this cycle would be inhibited. Currently, there are several therapeutic methods, including surgical resection, liver transplantation, radiofrequency ablation, TACE and systemic chemotherapy, which prevent HCC metastasis and recurrence. Immunotherapy is an important strategy for the treatment of HCC, which may maximize the killing of tumor cells without harming normal cells.
The crucial problem with HCC immunotherapy being implemented is the low efficiency of the immune response induced. It is precisely a phenomenon, in which the Treg cells are a major factor for inhibiting the specific tumor immune response in patients with HCC patients (26, 27) . Therefore, the induction of Treg cells may be reduced by destroying the tumor microenvironment to increase the efficacy of antitumor immune and HCC immunotherapy.
TACE is the preferred method of treatment for unresectable advanced HCC. Although TACE has been widely used clinically, it remains unclear if it may improve the immune status of patients with HCC and affect the quantity and function of Tregs. The present study demonstrated that the tumor volume of patients with HCC was substantially reduced following TACE treatment. In addition, the number of Treg cells in the peripheral blood decreased significantly, the proportion of CD4 + T cells and the ratio of CD4 + /CD8 + T cells increased by varying degrees. The Treg cells exhibited a positive correlation with the change of AFP prior to and following TACE. These results indicated that TACE improved the patients immune status and weakened the immune tolerance to increase the antitumor effects by reducing tumor burden and decreasing Tregs in the peripheral blood.
Previous studies demonstrated that Treg cells in patients with HCC performed tumor immune evasion by inhibiting NK cells and CD8 + cytotoxic T cells (15, 24, 25 
